Edwards Lifesciences recently exercised its option to acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement (TMVR) company. The company expects to pay about $300 million ...
Edwards Lifesciences is betting on a big opportunity in transcatheter mitral valve replacement, but offers up very few details on the status of its efforts in that area. Arundhati Parmar Edwards ...
Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making it the first minimally invasive, catheter-based treatment that uses a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results